<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04600544</url>
  </required_header>
  <id_info>
    <org_study_id>NS02-04</org_study_id>
    <nct_id>NCT04600544</nct_id>
  </id_info>
  <brief_title>Russian Disc Degeneration Study</brief_title>
  <acronym>RuDDS</acronym>
  <official_title>Disease-oriented Russian Disc Degeneration Study (RuDDS) Biobank Facilitating Functional Omics Studies of Lumbar Disc Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novosibirsk State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute of Cytology and Genetics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novosibirsk Research Institute of Traumatology and Orthopaedics n.a. Ya.L. Tsivyan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>N.N. Priorov National Medical Research Center of Traumatology and Orthopedics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Novosibirsk State University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of this study is to establish disease-oriented biobank to facilitate research in&#xD;
      biology of the lumbar disc degeneration. Diverse biological samples (whole blood, plasma,&#xD;
      disc tissue) along with MRI imaging, clinical, socio-demographic and various omics data (e.g.&#xD;
      genomic and transcriptomic) will be available for researchers and clinicians for a variety of&#xD;
      further multi-omics studies. It will lay the groundwork for the development of early&#xD;
      diagnostics of DDD and its personalized treatment.&#xD;
&#xD;
      The study is planned to enroll up to 1,100 patients with different grades of lumbar disc&#xD;
      degeneration. It is planned to recruit patients within 36 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2020</start_date>
  <completion_date type="Anticipated">January 19, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 19, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>Genotyping</measure>
    <time_frame>Through 3 years</time_frame>
    <description>DNA will be extracted from the whole blood samples according to the standard protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phenotype of patients with lumbar disc degeneration</measure>
    <time_frame>Through 3 years</time_frame>
    <description>General information about a patient, his medical history and MRI scans of lumbar spine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma proteins N-glycosylation profiling</measure>
    <time_frame>Through 3 years</time_frame>
    <description>The plasma glycans profiling will be performed according to standard protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total RNA profiling</measure>
    <time_frame>Through 3 years</time_frame>
    <description>The intraoperative material will be homogenized and total RNA will be extracted and converted to cDNA using Kit for the isolation of total RNA and microRNA from cells and tissues and M-MuLV-RH First Strand cDNA Synthesis Kit respectively. The amount of extracted RNA and its quality will be estimated using Bioanalyzer 2100.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Intervertebral Disc Degeneration</condition>
  <condition>Genetic Predisposition to Disease</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-interventional</intervention_name>
    <description>Translational, observational study</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood samples, plasma. Intervertebral lumbar disc samples only for patients subjected&#xD;
      for surgery.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants aged over 18 with available MRI scans of lumbar spine, who will also sign an&#xD;
        informed consent and meet all the eligibility criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age over 18;&#xD;
&#xD;
          2. Presence of lumbar MRI scans;&#xD;
&#xD;
          3. Signed informed consent for voluntary participation is provided.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any contraindication or inability to undergo baseline procedures;&#xD;
&#xD;
          2. Prior surgeries at any level of the lumbar spine;&#xD;
&#xD;
          3. Other non-degenerative spinal conditions that may have an impact on subject safety,&#xD;
             wellbeing or the intent and conduction of the study;&#xD;
&#xD;
          4. History or presence of HIV, hepatitis B, hepatitis C.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Olga Leonova, PhD, MD</last_name>
    <phone>+7 (383) 373-32-01</phone>
    <email>onleonova@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Priorov National Medical Research Center of Traumatology and Orthopedics</name>
      <address>
        <city>Moscow</city>
        <zip>127299</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aleksandr Krutko, PhD, MD</last_name>
      <phone>+7 (499) 940-97-47</phone>
      <email>ortho-ped@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Cytology and Genetics</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630090</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yakov Tsepilov, PhD</last_name>
      <phone>+7 (383) 363-49-86</phone>
      <email>tsepilov@bionet.nsc.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novosibirsk Research Institute of Traumatology and Orthopaedics n.a.Ya.L.Tsivyan</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630091</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Leonova, PhD, MD</last_name>
      <phone>+7 (383) 373-32-01</phone>
      <email>onleonova@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 19, 2020</study_first_submitted>
  <study_first_submitted_qc>October 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2020</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>biobank</keyword>
  <keyword>functional genomics</keyword>
  <keyword>transcriptomics</keyword>
  <keyword>glycomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
    <mesh_term>Disease Susceptibility</mesh_term>
    <mesh_term>Genetic Predisposition to Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>To access the database, omcis data and other relevant information, projects should be submitted to the steering committee (contact the Central Contact Person) of the RuDDS.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>During the study conducting and 5 years after</ipd_time_frame>
    <ipd_access_criteria>Contact the Central Contact Person onleonova@gmail.com</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

